Distinguished Physician-Scientist, Dr. Robert N. Weinreb, to Chair the Nemus Ophthalmology Advisory Board
COSTA MESA, CA -- (Marketwired) -- 09/28/15 -- Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that Robert N. Weinreb, M.D., an internationally recognized expert in diseases of the eye, has joined the Nemus Bioscience Scientific Advisory Board, including Chair of the Ophthalmology Board.
"Nemus is committed to advance the field of ocular therapeutics by introducing a new class of medicines derived from cannabinoid-based molecules. Development of these compounds has previously shown benefits in reducing intraocular pressure, especially in the setting of glaucoma, as well as neuroprotective qualities. Nemus is honored to have a physician of Dr. Weinreb's experience and reputation to provide both clinical and cutting-edge research guidance to the company as we advance our ophthalmology franchise," commented Brian Murphy, M.D., M.P.H., who serves as both CEO and Chief Medical Officer of Nemus. "He is a prolific investigator, as well as a skilled clinician, surgeon, and innovator."
A graduate of Harvard Medical School, Dr. Weinreb is Chairman and Distinguished Professor of Ophthalmology at the University of California, San Diego (UCSD), and also serves as Director of the Shiley Eye Institute. Dr. Weinreb's diverse research interests have focused on glaucoma, optic neuropathies, and disorders associated with the aging eye.
"Cannabinoid molecules have been recognized as impacting blood flow, intraocular pressure and apoptosis of retinal ganglion cells, but often a pivotal challenge has been therapeutic delivery to the eye. Nemus Bioscience is at the forefront of ocular-based cannabinoid drug development and is poised to leverage that expertise in developing therapies for eye diseases. I am looking forward to working with Nemus and the University of Mississippi in bringing re-engineered cannabinoid molecules through the development process to benefit patients with multiple types of eye disorders," noted Dr. Weinreb.
"Nemus will continue to add to our ophthalmology team as we advance our first candidate molecule for glaucoma, NB1111, a prodrug of THC, through development. We are thrilled with the addition of Dr. Weinreb and look to expand our library of cannabinoid-based molecules to optimize the therapeutic options for patients with eye disease," stated Dr. Murphy.
ABOUT NEMUS BIOSCIENCE, INC.
NEMUS is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. For more information, visit www.nemusbioscience.com.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.
Vice President -- MZ North America
Source: Nemus Bioscience
Released September 28, 2015